Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection

Oral Oncol. 2013 Jan;49(1):55-9. doi: 10.1016/j.oraloncology.2012.07.010. Epub 2012 Aug 1.

Abstract

Objectives: The optimal management of the N3 neck in head and neck squamous cell carcinoma (HNSCC) remains controversial. We report the outcomes of patients with N3 disease treated with a strategy of concurrent chemo-radiotherapy (CRT)±induction chemotherapy (ICT) without a planned neck dissection.

Materials and methods: Forty patients with HNSCC N3 disease treated between January 2004 and December 2010 were retrospectively identified. Inclusion criteria for the study were: non-nasopharyngeal HNSCC, N3 nodal disease, intention to treat with CRT±ICT.

Results: Median age was 60 (range 39-74). Median follow up was 32 months (range 8-88). 34 (85%) of patients received ICT. 35 patients received cisplatin-CRT, 4 carboplatin-CRT and 1 patient was treated with radiotherapy alone due to ICT toxicity. 27 (67.5%) patients had a complete response (CR) to CRT. 5 (12.5%) patients had an incomplete response in both the primary and nodal sites. 8 (20%) patients had a CR in the primary site but incomplete in the nodal regions. The crude rate of regional failure following a CR was 3/27 (11.2%). Isolated regional failure occurred in 1/27 (3.7%) patients who had achieved a CR post-CRT. 3 year overall survival, disease free survival, locoregional control, local control and regional control in the whole cohort were 51.4%, 49.6%, 65.7%, 77.3%, 69.3%, and in patients with a CR were 73.3%, 70.0%, 86.6%, 90.5% and 91.7% respectively.

Conclusion: Isolated regional nodal failure is rare following a complete response to CRT for N3 HNSCC managed without a planned neck dissection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy*
  • Cisplatin / administration & dosage
  • Disease-Free Survival
  • Docetaxel
  • Female
  • Fluorouracil / administration & dosage
  • Follow-Up Studies
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Induction Chemotherapy
  • Lymph Nodes / drug effects
  • Lymph Nodes / radiation effects
  • Male
  • Middle Aged
  • Neck Dissection
  • Neoplasm Staging
  • Radiotherapy, Conformal
  • Remission Induction
  • Retrospective Studies
  • Survival Rate
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Taxoids
  • Docetaxel
  • Carboplatin
  • Cisplatin
  • Fluorouracil